Radius Health Company Profile (NASDAQ:RDUS)

About Radius Health (NASDAQ:RDUS)

Radius Health logoRadius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, abaloparatide for subcutaneous injection, or abaloparatide-SC, has completed Phase III development for potential use in the treatment of women with postmenopausal osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch, or abaloparatide-TD, for potential use in the treatment of women with postmenopausal osteoporosis. In addition, the Company is evaluating its investigational product candidate, RAD1901, a selective estrogen receptor down-regulator/degrader (SERD) for potential use in the treatment of hormone-driven and/or hormone-resistant breast cancer, as well as for potential use in the treatment of vasomotor symptoms in postmenopausal women.

Industry, Sector and Symbol:
  • Sector:
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RDUS
  • CUSIP: N/A
  • Web: www.radiuspharm.com
Capitalization:
  • Market Cap: $1.52 billion
  • Outstanding Shares: 43,377,000
Average Prices:
  • 50 Day Moving Avg: $36.46
  • 200 Day Moving Avg: $41.83
  • 52 Week Range: $31.58 - $59.88
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.70
  • P/E Growth: -2.74
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $6.06 per share
  • Price / Book: 5.76
Profitability:
  • EBIDTA: ($200,700,000.00)
  • Return on Equity: -40.09%
  • Return on Assets: -38.09%
Debt:
  • Current Ratio: 14.76%
  • Quick Ratio: 14.76%
Misc:
  • Average Volume: 1.09 million shs.
  • Beta: 1.54
  • Short Ratio: 7.78
 

Frequently Asked Questions for Radius Health (NASDAQ:RDUS)

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

How were Radius Health's earnings last quarter?

Radius Health Inc (NASDAQ:RDUS) released its quarterly earnings results on Thursday, May, 4th. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.18) by $0.14. During the same period in the previous year, the business posted ($0.94) EPS. View Radius Health's Earnings History.

Where is Radius Health's stock going? Where will Radius Health's stock price be in 2017?

7 brokerages have issued 1-year price objectives for Radius Health's shares. Their forecasts range from $24.00 to $85.00. On average, they expect Radius Health's stock price to reach $56.83 in the next year. View Analyst Ratings for Radius Health.

What are analysts saying about Radius Health stock?

Here are some recent quotes from research analysts about Radius Health stock:

  • 1. According to Zacks Investment Research, "The FDA’s approval of Radius Health’s lead drug, Tymlos, is a significant boost for the company. However, the company’s wider-than-expected loss in the first quarter was disappointing as expenses continues to rise. Although the osteoporosis market in the U.S. has great potential as approximately 1.4 million postmenopausal women in the U.S. experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly & Co's Forteo and Amgen Inc's Prolia. Moreover, the approved label carries a boxed warning of osteosarcoma (a malignant bone tumor). Hence, we expect investors to focus on the drug’s pricing and uptake post launch. The company’ shares have underperformed the Zacks classified Medical-Drugs industry in the last six months. Loss estimates for 2017 have widened following the company’s first-quarter results." (5/4/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: April 28, 2017, 11:13 ET Date and time of production: April 28, 2017, 11:13 ET Target Price / Valuation Methodology: Radius Health – RDUS Our $85 price target is based on a probability adjusted EV/S methodology." (4/28/2017)
  • 3. Cantor Fitzgerald analysts commented, "RDUS shares are rallying this morning (+2%) on FDA approval of TYMLOS (abaloparatide-SC) ahead of expectations, as the extended PDUFA was June." (4/28/2017)

Are investors shorting Radius Health?

Radius Health saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 10,237,119 shares, an increase of 26.7% from the April 28th total of 8,080,441 shares. Based on an average daily volume of 1,426,182 shares, the days-to-cover ratio is currently 7.2 days. Approximately 26.1% of the company's stock are short sold.

Who are some of Radius Health's key competitors?

Who are Radius Health's key executives?

Radius Health's management team includes the folowing people:

  • Kurt C. Graves, Independent Chairman of the Board
  • Robert E. Ward, President, Chief Executive Officer, Director
  • B. Nicholas Harvey, Chief Financial Officer, Senior Vice President, Treasurer, Secretary
  • Gary Hattersley Ph.D., Senior Vice President, Chief Scientific Officer
  • Brent Hatzis-Schoch, Senior Vice President, General Counsel
  • Dinesh Purandare, Senior Vice President, Head of Global Oncology
  • Lorraine A. Fitzpatrick M.D., Chief Medical Officer
  • David P. Snow, Chief Commercial Officer
  • Gregory Williams Ph.D., Chief Development Officer
  • Alan H. Auerbach, Independent Director

Who owns Radius Health stock?

Radius Health's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (12.59%), BB Biotech AG (10.51%), Vanguard Group Inc. (6.97%), BlackRock Inc. (6.09%), State Street Corp (3.81%) and Jennison Associates LLC (2.22%). Company insiders that own Radius Health stock include Gary Hattersley, Growth N V Biotech, Kurt Graves and Rob Ward. View Institutional Ownership Trends for Radius Health.

Who sold Radius Health stock? Who is selling Radius Health stock?

Radius Health's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, State Street Corp, Commerzbank Aktiengesellschaft FI, JPMorgan Chase & Co., Wells Fargo & Company MN, Morgan Stanley, UBS Group AG and Alliancebernstein L.P.. View Insider Buying and Selling for Radius Health.

Who bought Radius Health stock? Who is buying Radius Health stock?

Radius Health's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Credit Agricole S A, BB Biotech AG, Bank of New York Mellon Corp, Vanguard Group Inc., Jennison Associates LLC, Pictet Asset Management Ltd. and Credit Suisse AG. View Insider Buying and Selling for Radius Health.

How do I buy Radius Health stock?

Shares of Radius Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Radius Health's stock price today?

One share of Radius Health stock can currently be purchased for approximately $34.93.


MarketBeat Community Rating for Radius Health (NASDAQ RDUS)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  293
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Radius Health (NASDAQ:RDUS) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $56.83 (62.71% upside)

Analysts' Ratings History for Radius Health (NASDAQ:RDUS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/24/2017Maxim GroupSet Price TargetSell$24.00LowView Rating Details
5/22/2017Cantor FitzgeraldSet Price TargetBuy$65.00LowView Rating Details
5/22/2017Canaccord GenuityReiterated RatingBuy$85.00LowView Rating Details
5/15/2017HC WainwrightReiterated RatingBuy$63.00LowView Rating Details
5/2/2017Jefferies Group LLCLower Price TargetHold$40.00 -> $34.00MediumView Rating Details
5/2/2017Cowen and CompanyDowngradeOutperform -> Market PerformLowView Rating Details
3/11/2017JPMorgan Chase & Co.Reiterated RatingBuyMediumView Rating Details
3/30/2016Goldman Sachs Group IncInitiated CoverageNeutral$37.00N/AView Rating Details
1/25/2016Bank of America CorpReiterated RatingBuy$89.00N/AView Rating Details
8/14/2015Deutsche Bank AGInitiated CoverageBuy$90.00N/AView Rating Details
(Data available from 5/30/2015 forward)

Earnings

Earnings History for Radius Health (NASDAQ:RDUS)
Earnings by Quarter for Radius Health (NASDAQ:RDUS)
Earnings History by Quarter for Radius Health (NASDAQ RDUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($1.18)($1.32)ViewListenView Earnings Details
2/23/2017Q416($1.34)($1.22)ViewN/AView Earnings Details
11/3/2016Q316($1.03)($1.07)$0.75 millionViewN/AView Earnings Details
8/4/2016Q216($0.95)($1.01)ViewN/AView Earnings Details
5/5/2016Q116($0.74)($0.94)ViewN/AView Earnings Details
2/25/2016Q415($0.64)($0.77)ViewListenView Earnings Details
11/5/2015Q315($0.58)($0.68)ViewN/AView Earnings Details
8/6/2015Q215($0.52)($0.61)ViewN/AView Earnings Details
5/6/2015Q115($0.52)($0.47)ViewN/AView Earnings Details
3/10/2015Q414($0.63)($0.55)ViewN/AView Earnings Details
11/10/2014Q314($0.65)($0.59)ViewN/AView Earnings Details
8/12/2014Q2($0.89)($2.22)$16.24 million$10.62 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Radius Health (NASDAQ:RDUS)
2017 EPS Consensus Estimate: ($4.49)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.94)($0.94)($0.94)
Q2 20171($1.37)($1.37)($1.37)
Q3 20171($1.16)($1.16)($1.16)
Q4 20171($1.02)($1.02)($1.02)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Radius Health (NASDAQ:RDUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Radius Health (NASDAQ:RDUS)
Insider Ownership Percentage: 16.80%
Institutional Ownership Percentage: 95.84%
Insider Trades by Quarter for Radius Health (NASDAQ:RDUS)
Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)
Insider Trades by Quarter for Radius Health (NASDAQ:RDUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/18/2017Growth N V BiotechMajor ShareholderBuy50,000$34.41$1,720,500.00View SEC Filing  
5/17/2017Growth N V BiotechMajor ShareholderBuy35,000$33.44$1,170,400.00View SEC Filing  
5/12/2017Growth N V BiotechMajor ShareholderBuy15,000$34.00$510,000.00View SEC Filing  
5/9/2017Growth N V BiotechMajor ShareholderBuy50,000$35.93$1,796,500.00View SEC Filing  
5/8/2017Growth N V BiotechMajor ShareholderBuy43,400$35.57$1,543,738.00View SEC Filing  
5/2/2017Growth N V BiotechMajor ShareholderBuy75,000$33.91$2,543,250.00View SEC Filing  
5/1/2017Growth N V BiotechMajor ShareholderBuy150,000$35.39$5,308,500.00View SEC Filing  
3/21/2017Growth N V BiotechMajor ShareholderBuy50,000$35.83$1,791,500.00View SEC Filing  
3/17/2017Growth N V BiotechMajor ShareholderBuy30,000$38.41$1,152,300.00View SEC Filing  
3/15/2017Growth N V BiotechMajor ShareholderBuy61,721$39.97$2,466,988.37View SEC Filing  
3/10/2017Growth N V BiotechMajor ShareholderBuy38,279$39.17$1,499,388.43View SEC Filing  
1/22/2016Growth N V BiotechMajor ShareholderBuy38,259$31.67$1,211,662.53View SEC Filing  
1/13/2016Growth N V BiotechMajor ShareholderBuy50,000$39.90$1,995,000.00View SEC Filing  
11/12/2015Gary HattersleyinsiderSell5,683$75.00$426,225.00View SEC Filing  
11/3/2015Gary HattersleyinsiderSell13,333$70.00$933,310.00View SEC Filing  
10/23/2015Gary HattersleyinsiderSell11,302$65.00$734,630.00View SEC Filing  
10/21/2015Gary HattersleyinsiderSell1,501$65.36$98,105.36View SEC Filing  
10/21/2015Rob WardCEOSell50,000$61.99$3,099,500.00View SEC Filing  
8/21/2015Growth N. V. Biotechmajor shareholderBuy100,000$64.00$6,400,000.00View SEC Filing  
8/17/2015Kurt GravesDirectorSell22,694$70.00$1,588,580.00View SEC Filing  
7/6/2015Kurt GravesDirectorSell25,000$69.48$1,737,000.00View SEC Filing  
6/18/2015Kurt GravesDirectorSell25,000$55.05$1,376,250.00View SEC Filing  
5/1/2015Growth N V BiotechMajor ShareholderBuy50,000$36.46$1,823,000.00View SEC Filing  
4/29/2015Growth N V BiotechMajor ShareholderBuy50,000$36.23$1,811,500.00View SEC Filing  
4/28/2015Growth N V BiotechMajor ShareholderBuy50,000$36.59$1,829,500.00View SEC Filing  
4/27/2015Growth N V BiotechMajor ShareholderBuy50,000$38.38$1,919,000.00View SEC Filing  
3/6/2015Growth N V BiotechMajor ShareholderBuy75,000$47.08$3,531,000.00View SEC Filing  
2/25/2015Growth N V BiotechMajor ShareholderBuy35,000$45.74$1,600,900.00View SEC Filing  
6/11/2014Morana Jovan-EmbiricosDirectorBuy587,500$8.00$4,700,000.00View SEC Filing  
6/6/2014Growth N V BiotechMajor ShareholderBuy1,000,000$8.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Radius Health (NASDAQ:RDUS)
Latest Headlines for Radius Health (NASDAQ:RDUS)
Source:
DateHeadline
americanbankingnews.com logoHC Wainwright Reiterates Buy Rating for Radius Health Inc (RDUS)
www.americanbankingnews.com - May 29 at 8:18 AM
americanbankingnews.com logoShort Interest in Radius Health Inc (RDUS) Grows By 26.7%
www.americanbankingnews.com - May 26 at 7:14 AM
americanbankingnews.com logoRadius Health Inc (RDUS) Given a $24.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - May 25 at 4:56 PM
streetinsider.com logoRadius Health (RDUS) Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS
www.streetinsider.com - May 24 at 7:52 PM
rttnews.com logoRadius Health Inc. (RDUS) Is Rising On Study Results
www.rttnews.com - May 24 at 7:52 PM
finance.yahoo.com logoRadius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS™ in Postmenopausal Women with Osteoporosis
finance.yahoo.com - May 24 at 7:52 PM
americanbankingnews.com logoRadius Health Inc (RDUS) Given a $65.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 23 at 8:04 PM
seekingalpha.com logoRadius Health (RDUS) Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow
seekingalpha.com - May 23 at 9:40 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Radius Health and Biocept Inc.
finance.yahoo.com - May 23 at 9:40 AM
finance.yahoo.com logoBiotech Movers: Radius Health, Amgen, Paratek
finance.yahoo.com - May 22 at 6:36 PM
finance.yahoo.com logoAmgen Can Shrug Off Its Bone-Drug Risks
finance.yahoo.com - May 22 at 6:36 PM
americanbankingnews.com logoRadius Health Inc (RDUS) Major Shareholder Growth N. V. Biotech Acquires 50,000 Shares
www.americanbankingnews.com - May 22 at 4:29 PM
americanbankingnews.com logoRadius Health Inc (RDUS) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - May 22 at 12:44 PM
americanbankingnews.com logoInsider Buying: Radius Health Inc (RDUS) Major Shareholder Buys 35,000 Shares of Stock
www.americanbankingnews.com - May 18 at 1:15 PM
americanbankingnews.com logoInsider Buying: Radius Health Inc (RDUS) Major Shareholder Acquires 15,000 Shares of Stock
www.americanbankingnews.com - May 16 at 1:21 PM
finance.yahoo.com logoRadius Health Announces New Employment Inducement Grant
finance.yahoo.com - May 15 at 6:42 PM
finance.yahoo.com logoRadius Health Appoints Pharmaceutical Executive Jose Carmona as Chief Financial Officer
finance.yahoo.com - May 15 at 9:39 AM
finance.yahoo.com logoRADIUS HEALTH, INC. (RDUS)
finance.yahoo.com - May 13 at 1:59 AM
americanbankingnews.com logoCantor Fitzgerald Weighs in on Radius Health Inc's FY2017 Earnings (RDUS)
www.americanbankingnews.com - May 12 at 12:33 PM
americanbankingnews.com logoRadius Health Inc (RDUS) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 12 at 8:48 AM
americanbankingnews.com logoGrowth N. V. Biotech Acquires 50,000 Shares of Radius Health Inc (RDUS) Stock
www.americanbankingnews.com - May 11 at 4:28 PM
prnewswire.com logoResearch Reports Coverage on Healthcare Stocks -- Radius Health, bluebird bio, Universal Health Services, and ... - PR Newswire (press release)
www.prnewswire.com - May 11 at 8:19 AM
seekingalpha.com logoRadius Health's Tymlos: How It Compares To The Competition - Seeking Alpha
seekingalpha.com - May 10 at 7:44 PM
americanbankingnews.com logoRadius Health Inc (RDUS) Major Shareholder Growth N. V. Biotech Buys 43,400 Shares
www.americanbankingnews.com - May 9 at 4:36 PM
americanbankingnews.com logoRadius Health's (RDUS) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - May 7 at 10:02 AM
americanbankingnews.com logoRadius Health Inc (RDUS) Expected to Announce Quarterly Sales of $2.2 Million
www.americanbankingnews.com - May 6 at 8:46 AM
marketwatch.com logoRadius Health, Inc. (US: RDUS) to Ring The Nasdaq Stock Market Opening Bell
www.marketwatch.com - May 5 at 12:43 AM
nasdaq.com logoRadius Health, Inc. (Nasdaq: RDUS) to Ring The Nasdaq Stock Market Opening Bell - Nasdaq
www.nasdaq.com - May 4 at 7:42 PM
americanbankingnews.com logoRadius Health Inc (RDUS) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 4 at 5:30 PM
americanbankingnews.com logoRadius Health Inc (RDUS) Expected to Post Earnings of -$1.33 Per Share
www.americanbankingnews.com - May 4 at 4:12 PM
americanbankingnews.com logoJefferies Group Comments on Radius Health Inc's Q2 2017 Earnings (RDUS)
www.americanbankingnews.com - May 4 at 11:50 AM
finance.yahoo.com logoInvestor Network: Radius Health Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 12:29 AM
americanbankingnews.com logoRadius Health Inc (RDUS) Major Shareholder Buys $2,543,250.00 in Stock
www.americanbankingnews.com - May 3 at 6:58 PM
americanbankingnews.com logoBrokers Set Expectations for Radius Health Inc's FY2021 Earnings (RDUS)
www.americanbankingnews.com - May 3 at 6:38 PM
americanbankingnews.com logoPositive Press Coverage Somewhat Likely to Affect Radius Health (RDUS) Stock Price
www.americanbankingnews.com - May 3 at 1:01 AM
americanbankingnews.com logoRadius Health Inc (RDUS) Major Shareholder Buys $5,308,500.00 in Stock
www.americanbankingnews.com - May 2 at 6:42 PM
seekingalpha.com logoRadius Health down another 4.7% on Tymlos launch concerns - Seeking Alpha
seekingalpha.com - May 2 at 5:18 PM
nasdaq.com logoRadius Health (RDUS) Posts Wider Q1 Loss, Tymlos Approved - Nasdaq
www.nasdaq.com - May 2 at 5:18 PM
americanbankingnews.com logoRadius Health Inc (RDUS) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - May 2 at 5:14 PM
finance.yahoo.com logoEdited Transcript of RDUS earnings conference call or presentation 1-May-17 11:30am GMT
finance.yahoo.com - May 2 at 9:50 AM
americanbankingnews.com logoRadius Health Inc (RDUS) Rating Reiterated by Maxim Group
www.americanbankingnews.com - May 1 at 9:10 PM
finance.yahoo.com logoRadius Health Reports First Quarter 2017 Financial and Operating Results
finance.yahoo.com - May 1 at 6:48 PM
finance.yahoo.com logoWhy Radius Health Inc. Is Dropping Today
finance.yahoo.com - May 1 at 6:48 PM
americanbankingnews.com logoRadius Health Inc (RDUS) Posts Quarterly Earnings Results, Misses Estimates By $0.14 EPS
www.americanbankingnews.com - May 1 at 6:22 PM
marketbeat.com logoRadius Health reports 1Q loss
marketbeat.com - May 1 at 6:55 AM
americanbankingnews.com logoRadius Health (RDUS) Receives Daily Coverage Optimism Rating of 0.45
www.americanbankingnews.com - April 29 at 4:47 PM
americanbankingnews.com logoCantor Fitzgerald Reiterates "Buy" Rating for Radius Health Inc (RDUS)
www.americanbankingnews.com - April 29 at 1:26 PM
americanbankingnews.com logoCanaccord Genuity Reaffirms "Buy" Rating for Radius Health Inc (RDUS)
www.americanbankingnews.com - April 29 at 1:01 AM
finance.yahoo.com logoFDA approves Radius Health's osteoporosis drug Tymlos
finance.yahoo.com - April 28 at 8:32 PM
streetinsider.com logoRadius Health (RDUS) Announces FDA Approval for TYMLOS for Treatment of Postmenopausal Women with ... - StreetInsider.com
www.streetinsider.com - April 28 at 3:30 PM

Social

Chart

Radius Health (RDUS) Chart for Tuesday, May, 30, 2017

This page was last updated on 5/30/2017 by MarketBeat.com Staff